APDN RSI Chart
Last 7 days
35.1%
Last 30 days
-21.9%
Last 90 days
-19.3%
Trailing 12 Months
-54.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 17.5M | 16.1M | 13.4M | 9.0M |
2022 | 15.1M | 17.6M | 18.2M | 19.3M |
2021 | 5.0M | 6.3M | 9.0M | 11.6M |
2020 | 4.9M | 3.3M | 1.9M | 2.9M |
2019 | 3.9M | 4.9M | 5.4M | 5.1M |
2018 | 4.6M | 3.9M | 3.9M | 4.1M |
2017 | 4.1M | 5.2M | 4.8M | 4.5M |
2016 | 8.1M | 6.5M | 4.2M | 3.8M |
2015 | 4.2M | 5.7M | 9.0M | 9.1M |
2014 | 2.6M | 2.8M | 2.7M | 3.4M |
2013 | 1.5M | 1.6M | 2.0M | 2.3M |
2012 | 1.5M | 1.8M | 1.9M | 1.7M |
2011 | 744.3K | 856.6K | 968.8K | 1.2M |
2010 | 0 | 0 | 519.8K | 632.1K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 23, 2023 | shorrock clay | acquired | - | - | 91,667 | chief legal officer |
Mar 23, 2023 | jantzen beth | acquired | - | - | 91,667 | chief financial officer |
Mar 23, 2023 | murrah judith | acquired | - | - | 99,306 | cio and coo |
Mar 10, 2021 | anchin scott l | sold | -110,042 | 8.43301 | -13,049 | - |
Mar 05, 2021 | anchin scott l | acquired | 56,240 | 4.30992 | 13,049 | - |
Jun 26, 2020 | montgomery william w | bought | 577,500 | 5.25 | 110,000 | - |
Jun 26, 2020 | montgomery william w | bought | -692,000 | 8.65 | -80,000 | - |
Jun 18, 2020 | montgomery william w | bought | 210,000 | 5.25 | 40,000 | - |
Jun 09, 2020 | montgomery william w | bought | 393,750 | 5.25 | 75,000 | - |
Jun 09, 2020 | montgomery william w | bought | -316,560 | 7.914 | -40,000 | - |
Which funds bought or sold APDN recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 11, 2024 | VANGUARD GROUP INC | unchanged | - | -310,653 | 323,013 | -% |
Feb 14, 2024 | CITADEL ADVISORS LLC | new | - | 4,869 | 4,869 | -% |
Feb 14, 2024 | Royal Bank of Canada | unchanged | - | -1,000 | 1,000 | -% |
Feb 14, 2024 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | reduced | -48.39 | -127,807 | 44,628 | -% |
Feb 14, 2024 | TWO SIGMA SECURITIES, LLC | sold off | -100 | -15,507 | - | -% |
Feb 14, 2024 | AWM Investment Company, Inc. | sold off | -100 | -994,830 | - | -% |
Feb 14, 2024 | SABBY MANAGEMENT, LLC | sold off | -100 | -47,069,000 | - | -% |
Feb 14, 2024 | Creative Planning | unchanged | - | -6,209 | 6,457 | -% |
Feb 14, 2024 | BANK OF AMERICA CORP /DE/ | added | 4.92 | -183 | 210 | -% |
Feb 14, 2024 | STATE STREET CORP | unchanged | - | -46,405 | 46,678 | -% |
Unveiling Applied DNA Sciences Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Applied DNA Sciences Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
DHR | 184.1B | 23.9B | 38.82 | 7.71 | ||||
IDXX | 44.8B | 3.7B | 53.05 | 12.25 | ||||
A | 43.2B | 6.7B | 34.96 | 6.42 | ||||
DGX | 14.5B | 9.3B | 16.99 | 1.57 | ||||
CRL | 13.8B | 4.1B | 29.14 | 3.35 | ||||
MEDP | 12.4B | 1.9B | 43.86 | 6.58 | ||||
EXAS | 12.1B | 2.5B | -59.47 | 4.86 | ||||
NTRA | 10.9B | 1.1B | -25.12 | 10.09 | ||||
MID-CAP | ||||||||
NEOG | 3.3B | 918.7M | 284.21 | 3.64 | ||||
GH | 2.2B | 563.9M | -4.56 | 3.88 | ||||
SMALL-CAP | ||||||||
CDNA | 544.7M | 280.3M | -2.86 | 1.94 | ||||
ACRS | 89.4M | 31.2M | -1.01 | 2.86 | ||||
AWH | 35.5M | 9.2M | -1.95 | 3.86 | ||||
APDN | 7.3M | 9.0M | -1.01 | 0.81 | ||||
BIOC | 183.8K | 25.9M | -0.01 | 0.01 |
Applied DNA Sciences Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 14.3% | 891,164 | 779,736 | 2,917,341 | 4,407,614 | 5,262,752 | 3,559,317 | 4,296,371 | 6,147,283 | 4,165,706 | 3,039,735 | 1,700,320 | 2,671,542 | 1,616,141 | 313,989 | 431,516 | 552,473 | 633,519 | 1,672,842 | 2,053,457 | 778,468 | 884,322 |
Cost Of Revenue | -5.8% | 660,067 | 700,740 | 1,648,023 | 2,600,179 | 2,885,069 | 3,142,558 | 3,257,113 | 3,658,798 | 3,056,568 | 1,972,377 | 1,116,106 | 940,568 | 515,781 | 154,483 | 154,804 | 179,582 | 232,031 | 320,105 | 270,883 | 133,141 | 153,485 |
Gross Profit | 192.5% | 231,097 | 78,996 | 1,269,318 | 1,807,435 | 2,377,683 | 416,759 | 1,039,258 | 2,488,485 | 1,109,138 | 1,067,358 | 584,214 | 1,730,974 | 1,100,360 | - | - | - | - | - | - | - | - |
Operating Expenses | -5.4% | 4,020,163 | 4,249,996 | 4,128,427 | 4,511,459 | 3,596,661 | 4,669,065 | 3,895,902 | 4,642,721 | 5,815,715 | 5,652,720 | 4,025,923 | 4,046,965 | 4,073,462 | 4,105,162 | 3,465,506 | 3,055,099 | 3,012,906 | 3,216,582 | 3,214,206 | 3,277,964 | 3,926,996 |
S&GA Expenses | -6.8% | 3,084,348 | 3,311,089 | 3,292,304 | 3,522,715 | 2,625,357 | 3,756,184 | 3,032,877 | 3,572,680 | 4,735,619 | 3,528,202 | 2,883,812 | 3,091,227 | 3,309,654 | 2,783,181 | 2,589,042 | 2,285,544 | 2,373,413 | 2,259,529 | 2,407,223 | 2,528,914 | 3,082,380 |
R&D Expenses | -0.3% | 935,815 | 938,907 | 836,123 | 988,744 | 971,304 | 912,881 | 863,025 | 1,070,041 | 1,080,096 | 1,302,777 | 1,142,111 | 955,738 | 763,808 | 1,239,720 | 814,599 | 703,018 | 564,426 | 886,669 | 719,668 | 651,377 | 709,564 |
EBITDA Margin | -1.8% | -0.65 | -0.64 | -0.35 | -0.21 | -0.32 | -0.38 | -0.61 | -0.88 | -1.13 | -1.49 | -2.11 | -2.65 | - | - | - | - | - | - | - | - | - |
Interest Expenses | -19.2% | 33,323 | 41,224 | 26,783 | 3,639 | 3,686 | 1,387 | - | 5,540 | 273 | 1,700 | 3,572 | 13,841 | -5,438 | -29,019 | -28,624 | -29,096 | -29,091 | -55,226 | -38,177 | -37,417 | -31,611 |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15,000 | - | - | - |
Earnings Before Taxes | 68.7% | -1,130,281 | -3,615,651 | -3,114,195 | 551,176 | -3,844,246 | -664,554 | -1,124,796 | -1,759,797 | -4,720,911 | -4,507,584 | -3,446,715 | -1,517,078 | -4,807,062 | -4,125,146 | -3,290,112 | -2,950,905 | -2,662,741 | -1,218,458 | -1,477,911 | -2,686,757 | -3,234,320 |
EBT Margin | -8.4% | -0.81 | -0.75 | -0.44 | -0.29 | -0.38 | -0.46 | -0.69 | -0.96 | -1.23 | -1.58 | -2.21 | -2.73 | - | - | - | - | - | - | - | - | - |
Net Income | 69.1% | -1,105,100 | -3,573,680 | -3,099,766 | 551,176 | -3,843,372 | -663,091 | -1,124,220 | -1,759,797 | -4,720,911 | -4,512,201 | -3,448,993 | -1,517,078 | -4,807,062 | -4,123,528 | -3,289,450 | -2,950,905 | -2,662,741 | -1,224,135 | -1,477,911 | -2,686,757 | -3,234,320 |
Net Income Margin | -7.8% | -0.80 | -0.75 | -0.44 | -0.29 | -0.38 | -0.46 | -0.69 | -0.96 | -1.23 | -1.58 | -2.21 | -2.73 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -40.2% | -3,757,592 | -2,679,679 | -1,393,389 | 160,049 | -2,383,106 | -3,501,281 | -1,830,981 | -327,417 | -3,806,580 | -5,618,495 | -1,752,554 | -4,080,317 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -27.4% | 9,913 | 13,652 | 15,790 | 19,175 | 20,297 | 22,265 | 11,920 | 13,879 | 11,402 | 14,417 | 17,190 | 20,782 | 9,678 | 11,341 | 13,975 | 11,327 | 10,872 | 3,565 | 2,985 | 4,226 | 6,149 |
Current Assets | -43.5% | 4,590 | 8,127 | 12,240 | 15,380 | 18,332 | 19,943 | 9,268 | 11,156 | 8,499 | 11,298 | 13,696 | 17,419 | 6,540 | 9,078 | 12,155 | 9,979 | 9,638 | 2,146 | 1,605 | 2,763 | 4,600 |
Cash Equivalents | -53.0% | 3,359 | 7,152 | 10,756 | 12,287 | 12,877 | 15,215 | 4,682 | 6,513 | 2,748 | 6,555 | 12,173 | 13,926 | 4,241 | 7,787 | 10,925 | 8,663 | 8,663 | 559 | 507 | 1,541 | 3,138 |
Inventory | 14.3% | 377 | 330 | 276 | 366 | 477 | 602 | 1,172 | 1,411 | 1,301 | 1,370 | 429 | 721 | 543 | 497 | 445 | 89.00 | 83.00 | 143 | 310 | 315 | 225 |
Net PPE | -35.7% | 539 | 838 | 1,168 | 1,575 | 1,866 | 2,223 | 2,557 | 2,629 | 2,808 | 3,024 | 2,577 | 2,423 | 2,175 | 1,278 | 751 | 265 | 184 | 226 | 265 | 316 | 369 |
Goodwill | - | - | - | - | - | - | - | - | - | - | - | 285 | 285 | 285 | 285 | 285 | 285 | 285 | 285 | 285 | 285 | 285 |
Liabilities | -34.1% | 5,785 | 8,779 | 8,595 | 9,207 | 11,139 | 9,356 | 5,126 | 6,233 | 3,010 | 3,304 | 1,606 | 2,162 | 3,955 | 5,632 | 5,196 | 4,058 | 3,648 | 4,413 | 4,774 | 4,960 | 5,383 |
Current Liabilities | -9.0% | 2,588 | 2,845 | 2,891 | 3,655 | 3,330 | 4,185 | 4,284 | 3,633 | 2,979 | 3,272 | 1,575 | 2,130 | 2,919 | 4,266 | 2,448 | 1,850 | 1,509 | 2,246 | 1,974 | 2,220 | 2,733 |
Shareholder's Equity | -14.5% | 4,232 | 4,951 | 7,249 | 9,968 | 9,158 | 12,909 | 6,795 | 7,647 | 8,392 | 11,113 | 15,584 | 18,620 | 5,723 | 5,710 | 8,779 | 7,269 | 7,224 | - | - | - | 766 |
Retained Earnings | -0.4% | -303,630 | -302,447 | -298,854 | -295,755 | -296,343 | -292,500 | -291,836 | -290,712 | -288,843 | -284,122 | -279,611 | -276,162 | -274,645 | -269,835 | -265,712 | -262,423 | -259,471 | -256,805 | -255,271 | -253,793 | -251,107 |
Additional Paid-In Capital | 0.2% | 307,849 | 307,385 | 306,091 | 305,751 | 305,493 | 305,399 | 298,624 | 298,352 | 297,228 | 295,228 | 295,191 | 294,781 | 280,369 | 275,549 | 274,493 | 269,694 | 266,699 | 255,963 | 253,445 | 253,022 | 251,838 |
Shares Outstanding | 0% | 13,659 | 13,659 | 12,909 | 12,909 | 12,909 | 12,909 | 8,185 | 7,784 | 7,486 | 7,486 | 6,725 | 7,235 | - | - | - | - | - | - | - | - | - |
Minority Interest | -32.0% | -103 | -78.75 | -55.36 | -40.93 | -3.76 | -2.89 | -1.55 | -979* | 133* | -722* | -4.23 | -6.51 | -6.23 | -8.72 | -6.51 | -5.85 | -7.07 | -7.04 | - | - | - |
Float | - | - | - | - | 14,400 | - | - | - | 17,200 | - | - | - | 45,800 | - | - | - | 13,500 | - | - | - | 21,000 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -40.2% | -3,757 | -2,679 | -1,369 | 214 | -2,383 | -3,258 | -1,754 | -261 | -3,701 | -4,712 | -1,249 | -3,270 | -4,155 | -2,983 | -3,008 | -2,420 | -2,731 | -3,059 | - | -2,288 | -1,513 |
Share Based Compensation | -0.2% | 341 | 341 | 340 | 259 | 94.00 | 273 | 273 | 273 | 1,700 | 37.00 | 410 | 649 | 571 | 204 | 365 | 227 | 205 | 295 | 154 | 267 | 490 |
Cashflow From Investing | 100.0% | - | -924 | -161 | -54.34 | 45.00 | -242 | -76.67 | -65.53 | -104 | -906 | -502 | -810 | -329 | -1,007 | -11.43 | -44.75 | - | -3.45 | - | -11.93 | -52.05 |
Cashflow From Financing | -Infinity% | -35.08 | - | - | - | - | 14,035 | 75* | 4,092 | - | - | - | 13,765 | 940 | 852 | 5,282 | 2,465 | 10,835 | 2,081 | - | 704 | 3,044 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenues | ||
Total revenues | $ 891,164 | $ 5,262,752 |
Total cost of revenues | 660,067 | 2,885,069 |
Gross profit | 231,097 | 2,377,683 |
Operating expenses: | ||
Selling, general and administrative | 3,084,348 | 2,625,357 |
Research and development | 935,815 | 971,304 |
Total operating expenses | 4,020,163 | 3,596,661 |
LOSS FROM OPERATIONS | (3,789,066) | (1,218,978) |
Interest income | 33,323 | 3,686 |
Unrealized gain (loss) on change in fair value of warrants classified as a liability | 2,639,000 | (2,637,800) |
Other (expense) income, net | (13,538) | 8,846 |
Loss before provision for income taxes | (1,130,281) | (3,844,246) |
NET LOSS | (1,130,281) | (3,844,246) |
Less: Net loss attributable to noncontrolling interest | 25,181 | 874 |
NET LOSS attributable to Applied DNA Sciences, Inc. | (1,105,100) | (3,843,372) |
Deemed dividend related to warrant modifications | (77,757) | |
NET LOSS attributable to common stockholders | $ (1,182,857) | $ (3,843,372) |
Net loss per share attributable to common stockholders - basic | $ (0.09) | $ (0.30) |
Net loss per share attributable to common stockholders - diluted | $ (0.09) | $ (0.30) |
Weighted average shares outstanding - basic | 13,673,433 | 12,908,520 |
Weighted average shares outstanding - diluted | 13,673,433 | 12,908,520 |
Product revenues | ||
Revenues | ||
Total revenues | $ 307,317 | $ 516,396 |
Total cost of revenues | 282,545 | 365,378 |
Service revenues | ||
Revenues | ||
Total revenues | 247,147 | 232,061 |
Clinical laboratory service revenues | ||
Revenues | ||
Total revenues | 336,700 | 4,514,295 |
Total cost of revenues | $ 377,522 | $ 2,519,691 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) | Dec. 31, 2023 | Sep. 30, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 3,359,045 | $ 7,151,800 |
Accounts receivable, net of allowance of $75,000 at December 31, 2023 and September 30, 2023, respectively | 450,757 | 255,502 |
Inventories | 377,291 | 330,027 |
Prepaid expenses and other current assets | 402,953 | 389,241 |
Total current assets | 4,590,046 | 8,126,570 |
Property and equipment, net | 539,319 | 838,270 |
Other assets: | ||
Restricted cash | 750,000 | 750,000 |
Intangible assets | 2,698,975 | 2,698,975 |
Operating right of use asset | 1,117,317 | 1,237,762 |
Capitalized transaction costs | 217,553 | |
Total assets | 9,913,210 | 13,651,577 |
Current liabilities: | ||
Accounts payable and accrued liabilities | 2,023,876 | 2,270,388 |
Operating lease liability, current | 510,028 | 498,598 |
Deferred revenue | 54,035 | 76,435 |
Total current liabilities | 2,587,939 | 2,845,421 |
Long term accrued liabilities | 31,467 | 31,467 |
Deferred revenue, long term | 227,999 | 194,000 |
Operating lease liability, long term | 607,288 | 739,162 |
Deferred tax liability, net | 684,115 | 684,115 |
Warrants classified as a liability | 1,646,000 | 4,285,000 |
Total liabilities | 5,784,808 | 8,779,165 |
Commitments and contingencies (Note G) | ||
Applied DNA Sciences, Inc. stockholders' equity: | ||
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of Decenber 31, 2023 and September 30 2023, respectively | ||
Common stock, par value $0.001 per share; 200,000,000 shares authorized as of December 31, 2023 and September 30, 2023, 13,721,820 and 13,658,520 shares issued and outstanding as of December 31, 2023 and September 30, 2023, respectively | 13,722 | 13,659 |
Additional paid in capital | 307,848,612 | 307,384,647 |
Accumulated deficit | (303,630,004) | (302,447,147) |
Applied DNA Sciences, Inc. stockholders' equity | 4,232,330 | 4,951,159 |
Noncontrolling interest | (103,928) | (78,747) |
Total equity | 4,128,402 | 4,872,412 |
Total liabilities and equity | 9,913,210 | 13,651,577 |
Series A Preferred stock | ||
Applied DNA Sciences, Inc. stockholders' equity: | ||
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of Decenber 31, 2023 and September 30 2023, respectively | ||
Series B Preferred stock | ||
Applied DNA Sciences, Inc. stockholders' equity: | ||
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of Decenber 31, 2023 and September 30 2023, respectively |